News Conference News ACC 2023 MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis Michael O'Riordan March 10, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions Shelley Wood March 09, 2017